Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Turnstone Biologics Corp.

Get SEC filing alerts via email and in your feed for Turnstone Biologics Corp.

TSBX

Turnstone Biologics Corp.

About Turnstone Biologics Corp.

Turnstone Biologics is a biotechnology company focused on developing cancer immunotherapies, particularly tumor-infiltrating lymphocyte (TIL) and oncolytic viral therapies. Its pipeline includes innovative TIL and viral-based treatments targeting solid tumors. The company owns extensive intellectual property and collaborates with research institutions. It aims to advance immuno-oncology solutions, seeking regulatory approval and strategic transactions to maximize value in the cancer treatment market.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Turnstone Biologics Corp.

1
1
Turnstone Biologics Corp. Turnstone Biologics Reports $5.5M Net Loss, Plans Merger with XOMA Royalty Corporation

Via official filing (AI summary) | 11 months ago | 0 comments

2
1
Turnstone Biologics Corp. Turnstone Biologics Reports $11.8 Million Net Loss in Q1 2025, Discontinues Clinical Studies

Via official filing (AI summary) | about 1 year ago | 0 comments

3
1
Turnstone Biologics Corp. Turnstone Biologics Reports $70.8 Million Net Loss for 2024, Halts Clinical Trials

Via official filing (AI summary) | about 1 year ago | 0 comments

4
1
Turnstone Biologics Corp. Turnstone Biologics Reports Significant Financial Challenges, Net Loss of $57.965 Million in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments